J&J | JNJ - Zinsaufwendungen Für Schuld

Aktienkurs
240.97
Täglich Wechseln
-2.07 -0.85%
Monatlich
-0.67%
Jährlich
59.99%
Q2 Prognose
235.72




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Abbott USD 42M 2M 2025-12
Amgen USD 653M 32M 2025-12
AstraZeneca USD 484M 181M 2025-12
Baxter International USD 58M 14M 2025-09
Bayer EUR 675M 87M 2025-12
Becton, Dickinson and Co. USD 153M 2M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Boston Scientific USD 90M 3M 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
CONMED USD 7.37M 236K 2025-12
Cooper Companies USD 22.4M 2M 2025-12
Dexcom USD 4.7M 0 2025-09
Edwards Lifesciences USD 38.6M 1.2M 2025-09
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Globus Medical USD 17K 5.1B 2025-12
Hologic USD 27.6M 1000K 2025-12
Insulet USD 9.2M 2.2M 2025-12
Integra LifeSciences USD 23.67M 953K 2025-12
Intuitive Surgical USD 19.35B 811.4M 2025-09
J&J USD 18M 290M 2025-09
Medtronic USD 181M 0 2025-12
Merck USD 412M 85M 2025-12
Merit Medical Systems USD 6.36M 390K 2025-12
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR -25M 252M 2025-12
Stryker USD 157M 46.17B 2025-09
Tandem Diabetes Care USD 2.07M 872.58M 2025-12
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Zimmer Biomet Holdings USD 71.9M 3.5M 2025-12
Zoetis USD 57M 1000K 2025-12